Healthcare > Pharmaceuticals & Biotechnology
•2430 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2430)
| Company | Market Cap | Price |
|---|---|---|
|
KAPA
Kairos Pharma, Ltd.
KROS 101 is an immunotherapy GITR ligand agonist, aligning with immunology therapeutics.
|
$12.73M |
$0.61
-0.98%
|
|
INTS
Intensity Therapeutics, Inc.
Company develops oncology-focused therapeutics (INT230-6.00) and operates in Biotech - Oncology.
|
$12.73M |
$5.33
+0.19%
|
|
SNGX
Soligenix, Inc.
ThermoVax vaccine thermostabilization platform and RiVax vaccine program place Soligenix in Vaccines.
|
$12.61M |
$1.25
+6.41%
|
|
BCDA
BioCardia, Inc.
CardiAMP and CardiALLO are BioCardia's direct cell-therapy programs (autologous and allogeneic) targeted for cardiovascular disease.
|
$12.52M |
$1.19
|
|
CLRB
Cellectar Biosciences, Inc.
Core product category: radiopharmaceuticals developed and marketed by Cellectar as radioconjugate therapies.
|
$12.38M |
$2.88
-4.32%
|
|
LIPO
Lipella Pharmaceuticals Inc.
Lipella's core metastable liposome drug delivery platform enables targeted, localized mucosal drug formulations.
|
$12.20M |
$0.31
|
|
BIVI
BioVie Inc.
Bezisterim is described as an orally administered small molecule therapeutic targeting inflammation-driven insulin resistance in neurodegenerative diseases, aligning with 'Oral Small Molecule Therapeutics'.
|
$11.76M |
$1.56
+7.19%
|
|
GDTC
CytoMed Therapeutics Limited
Core business platform focuses on cell-based immunotherapies (gamma delta T cells, NK cells), aligning with Biotech - Cell Therapy.
|
$11.66M |
$1.00
-1.96%
|
|
PVCT
Provectus Biopharmaceuticals, Inc.
VisiRose EyeCo focuses on ophthalmic topical RBS (PV-305) for infectious keratitis, an ophthalmic drug product.
|
$11.47M |
$0.05
|
|
TRAW
Traws Pharma, Inc.
Company is developing Antiviral Small-Molecule Therapeutics (ratutrelvir) for COVID-19 as a core antiviral program.
|
$11.44M |
$1.57
-3.09%
|
|
MDXH
MDxHealth S.A.
GPS test provides biomarker-based risk stratification that informs treatment decisions, aligning with Companion Diagnostics.
|
$11.43M |
$2.31
+4.77%
|
|
BFRG
Bullfrog AI Holdings, Inc. Common Stock
Engages in external collaborations/partnerships to provide AI-driven drug development services, akin to CRO-type engagements.
|
$11.34M |
$1.00
-7.35%
|
|
PLRZ
Polyrizon Ltd.
Polyrizon's core offering is a proprietary intranasal hydrogel-based drug delivery platform (Capture & Contain and Trap & Target) used to deliver allergy blockers and CNS-targeted APIs.
|
$11.18M |
$11.43
+4.48%
|
|
ELTP
Elite Pharmaceuticals, Inc.
Elite focuses on the development, manufacture, and sale of generic drugs across a broad pipeline.
|
$11.18M |
$0.38
|
|
DSY
Big Tree Cloud Holdings Limited
Provides OEM/ODM manufacturing services, i.e., contract manufacturing for others.
|
$10.91M |
$2.59
-1.89%
|
|
CVKD
Cadrenal Therapeutics, Inc. Common Stock
Cadrenal's tecarfarin is described as a novel oral small-molecule therapeutic, directly aligning with the 'Oral Small Molecule Therapeutics' tag.
|
$10.84M |
$5.50
+13.40%
|
|
EUDA
EUDA Health Holdings Limited
EUDA's core biotech activity is a stem cell platform and cell therapy development using iPSCs.
|
$9.77M |
$6.39
+7.58%
|
|
BCAB
BioAtla, Inc.
Oz-V and Mec-V are ADCs (CAB-ROR2-ADC, CAB-AXL-ADC) - major product modality.
|
$9.65M |
$0.17
+4.02%
|
|
NOTV
Inotiv, Inc.
Inotiv operates as a CRO delivering nonclinical drug discovery and development services, aligning with the Contract Research Organizations tag.
|
$9.52M |
$0.29
-1.66%
|
|
QNRX
Quoin Pharmaceuticals, Ltd.
Lead program targets a rare disease (Netherton Syndrome) and is developed by a biotech focused on rare diseases.
|
$9.48M |
$6.42
-2.43%
|
|
NXGL
NEXGEL, Inc.
NXGEL generates revenue from contract manufacturing of hydrogel-based medical and consumer products.
|
$9.28M |
$1.21
+0.42%
|
|
KPRX
Kiora Pharmaceuticals, Inc.
Company's pipeline focuses on ophthalmic therapeutics (KIO-301, KIO-104) targeting retinal degenerative diseases and retinal inflammation, i.e., Ophthalmic Drugs.
|
$9.27M |
$2.55
+2.41%
|
|
IMNN
Imunon, Inc.
IMUNON's lead candidate IMNN-001 targets ovarian cancer, aligning with Biotech - Oncology.
|
$9.10M |
$4.16
+0.73%
|
|
BOLT
Bolt Biotherapeutics, Inc.
Bolt is a clinical-stage biotech focused on oncology immunotherapies, making 'Biotech - Oncology' a core investable theme.
|
$9.08M |
$4.87
+1.25%
|
|
PAVM
PAVmed Inc.
PAVmed's biopharma expansion targets oncology assets, aligning with Biotech - Oncology.
|
$9.02M |
$9.39
+3.07%
|
|
EPIX
ESSA Pharma Inc.
Directly describes a biotech company focused on oncology drug development (masofaniten) with no revenue; core business is cancer therapeutics.
|
$8.93M |
$0.20
|
|
OSRH
OSR Holdings, Inc.
VAXIMM's lead oncology immunotherapy candidate positions OSRH in the Biotech - Oncology space.
|
$8.89M |
$0.41
-1.48%
|
|
CALC
CalciMedica, Inc.
CalciMedica's lead candidate Auxora is a CRAC channel inhibitor, i.e., an ion channel modulator.
|
$8.69M |
$0.61
-0.03%
|
|
MDCX
Medicus Pharma Ltd. Common Stock
Directly markets/provides a proprietary drug-delivery platform (D-MNA) enabling localized chemotherapy delivery.
|
$8.68M |
$0.35
+15.22%
|
|
BCTX
BriaCell Therapeutics Corp.
BriaCell's core focus is oncology immunotherapies, aligning with Biotech - Oncology.
|
$8.35M |
$4.40
+1.85%
|
|
TSBX
Turnstone Biologics Corp.
Company's core business is oncology-focused biotechnology, including immunotherapy approaches (TIL-based strategies) in solid tumors.
|
$8.21M |
$0.35
|
|
RNAZ
TransCode Therapeutics, Inc.
TransCode Therapeutics operates in biotech oncology, developing cancer therapeutics.
|
$8.07M |
$8.76
+0.63%
|
|
CRIS
Curis, Inc.
Emavusertib is an orally available, small-molecule therapeutic targeting IRAK4/FLT3.
|
$7.80M |
$0.60
+1.42%
|
Showing page 22 of 25 (2430 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
